Fluoxetine: Difference between revisions
No edit summary |
|||
Line 14: | Line 14: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[ | ==FLUOXETINE (fluoxetine hydrochloride) solution Normal 0 false false false EN-US X-NONE X-NONE == | ||
'''| [[ | |||
'''| [[ | ''' [[FLUOXETINE (fluoxetine hydrochloride) solution indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution description|Description]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[FLUOXETINE (fluoxetine hydrochloride) solution how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution patient counseling information|Patient Counseling Information]]''' | |||
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution labels and packages|Labels and Packages]]''' | |||
==PROZAC (fluoxetine hydrochloride) capsule== | |||
Normal 0 false false false EN-US X-NONE X-NONE Normal 0 false false false EN-US X-NONE X-NONE | |||
''' [[PROZAC (fluoxetine hydrochloride) capsule indications and usage|Indications and Usage]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule dosage and administration|Dosage and Administration]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule contraindications|Contraindications]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule adverse reactions|Adverse Reactions]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule drug interactions|Drug Interactions]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule use in specific populations|Use in Specific Populations]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule overdosage|Overdosage]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule description|Description]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule clinical studies|Clinical Studies]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule patient counseling information|Patient Counseling Information]]''' | |||
'''| [[PROZAC (fluoxetine hydrochloride) capsule labels and packages|Labels and Packages]]''' | |||
==PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release Normal 0 false false false EN-US X-NONE X-NONE == | |||
''' [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release indications and usage|Indications and Usage]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release dosage and administration|Dosage and Administration]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release contraindications|Contraindications]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release adverse reactions|Adverse Reactions]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release drug interactions|Drug Interactions]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release use in specific populations|Use in Specific Populations]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release overdosage|Overdosage]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release description|Description]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release clinical studies|Clinical Studies]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release patient counseling information|Patient Counseling Information]]''' | |||
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | ==Mechanism of Action== |
Revision as of 20:14, 12 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information about Fluoxetine, click here.
Synonyms / Brand Names: Fluoxetinum®, Fluoxetine Hydrochloride®, Fluoxetine Hcl®, Fluoxetina®, Fluoxetina®, Animex-On®, Deprex®, Eufor®, Fluctin®, Fluoxeren®, Fluval®, Fontex®, Foxetin®, Portal®, Prozac®, Prozac Weekly®, Pulvules®, Reneuron®, Sarafem®, Adofen®
Overview
Category
FDA Package Insert
FLUOXETINE (fluoxetine hydrochloride) solution Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
PROZAC (fluoxetine hydrochloride) capsule
Normal 0 false false false EN-US X-NONE X-NONE Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Dosing and Administration
Major Depressive Disorder
Adult — In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day.
Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major
depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose.
A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above 20 mg/day may be
administered on a once-a-day (morning) or BID schedule (i.e., morning and noon) and should not exceed a maximum dose of 80 mg/day.
Obsessive-Compulsive Disorder
Adult — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily
doses of 20, 40, or 60 mg of fluoxetine or placebo. In 1 of these studies, no dose-response relationship for effectiveness was
demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of
a possible dose-response relationship for effectiveness in the second study, a dose increase may be considered after several weeks if insufficient
clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.
Doses above 20 mg/day may be administered on a once-a-day (i.e., morning) or BID schedule (i.e., morning and noon). A dose range of 20 to
60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluoxetine dose
should not exceed 80 mg/day.
Bulimia Nervosa
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of bulimia nervosa, patients were administered fixed daily
fluoxetine doses of 20 or 60 mg, or placebo. Only the 60-mg dose was statistically significantly superior to placebo in
reducing the frequency of binge-eating and vomiting. Consequently, the recommended dose is 60 mg/day, administered in the morning. For some
patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically
studied in patients with bulimia.
Panic Disorder
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of panic disorder, patients were administered fluoxetine
doses in the range of 10 to 60 mg/day. Treatment should be initiated with a dose of 10 mg/day. After 1 week, the dose should
be increased to 20 mg/day. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day.
For more detailed information on dosing please refer to Instructions for administration
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Fluoxetine
Return to top
Publication Resources
Most Recent Articles on Fluoxetine
Review Articles on Fluoxetine
Articles on Fluoxetine in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Fluoxetine
Return to top
Trial Resources
Ongoing Trials with Fluoxetine at Clinical Trials.gov
Trial Results with Fluoxetine
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Fluoxetine
Cochrane Collaboration on Fluoxetine
Cost Effectiveness of Fluoxetine
Return to top
Media Resources
Powerpoint Slides on Fluoxetine
Images of Fluoxetine
Podcasts & MP3s on Fluoxetine
Videos on Fluoxetine
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Fluoxetine
Discussion Groups on Fluoxetine
Patient Handouts on Fluoxetine
Blogs on Fluoxetine
Fluoxetine in the News
Fluoxetine in the Marketplace
Return to top
International Resources
Fluoxetine en Español
Return to top
References
Template:Antimigraine preparations
Adapted from the FDA Package Insert.